Category Archives for News

Sera Prognostics to Present at Baird’s 2020 Global Health Care Conference

June 24, 2020 – Sera announced the appointment Thomas J. Garite, M.D. as Vice President of Clinical Sciences. – Dr. Garite will support clinical development and operations as Sera transitions from clinical to commercial-stage company.

Read More

Sera Prognostics Appoints Thomas J. Garite, M.D. as Vice President of Clinical Sciences

June 24, 2020 – Sera announced the appointment Thomas J. Garite, M.D. as Vice President of Clinical Sciences. – Dr. Garite will support clinical development and operations as Sera transitions from clinical to commercial-stage company.

Read More

Publication Demonstrates Ability of Sera Prognostics’ PreTRM® Biomarker Test as a Predictor of Adverse Pregnancy Outcomes

May 20, 2020 – SALT LAKE CITY — Sera Prognostics, Inc., The Pregnancy Company® focused on improving maternal and neonatal health through innovative precision biomarker approaches, today announced the publication of positive data in a large, independent, contemporary prospective U.S. clinical cohort study, TREETOP (NCT02787213), in the American Journal of Obstetrics & Gynecology Maternal Fetal […]

Read More

Premature Birth Survey Uncovers That Expecting Parents Want To Know if They Are at Risk for a Preterm Birth

SALT LAKE CITY, January 10, 2017– LabCorp Leads $40 Million Series C Financing as Sera Expands its Activities to Address Premature Birth. Sera Prognostics, Inc., a woman’s healthcare company, announced today that it has entered into a strategic collaboration with Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH), a world leading life sciences company, to be the exclusive U.S. distributor of Sera’s PreTRM® test. PreTRM is the first and only clinically-validated blood test that provides an early and individualized prediction of preterm birth risk.

Read More

Sera Prognostics Enters into Agreement with LabCorp to be the Exclusive U.S. Distributor of PreTRM® Test

SALT LAKE CITY, January 10, 2017– LabCorp Leads $40 Million Series C Financing as Sera Expands its Activities to Address Premature Birth. Sera Prognostics, Inc., a woman’s healthcare company, announced today that it has entered into a strategic collaboration with Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH), a world leading life sciences company, to be the exclusive U.S. distributor of Sera’s PreTRM® test. PreTRM is the first and only clinically-validated blood test that provides an early and individualized prediction of preterm birth risk.

Read More

Sera Prognostics’ PreTRM® Named Edison Awards Finalist

SALT LAKE CITY, February 9, 2017 – Sera Prognostics, a women’s heath company, today announced that PreTRM®, the first and only clinically-validated blood test that provides an early and individualized prediction of preterm birth risk, has been named a 2017 Award Finalist by the internationally renowned Edison Awards™.

Read More

Sera Prognostics is named a 2017 Silver Edison Award Winner

New York, NY – April 21, 2017 – The Edison Awards, celebrating 30 years of honoring the best in innovation and excellence in the development of new products and services, announced today that Sera Prognostics’ PreTRM Test was voted a Silver Winner for innovation in the “Health and Wellness” category at the April 20th event at The Capitale in New York City.

Read More

Positive Clinical Validation Data for PreTRM® Test Presented at the Society for Maternal-Fetal Medicine’s 36th Annual Pregnancy Meeting

February 4, 2016 – Sera Prognostics, Inc., a women’s healthcare company, today announced that results from the 5,501-patient Proteomic Assessment of Preterm Risk (PAPR) study validate the newly available PreTRM® test, which accurately and objectively predicts spontaneous preterm birth (sPTB), in pregnant women whose blood is drawn for analysis as early as 19 weeks of pregnancy. The data were presented at the Society for Maternal-Fetal Medicine’s 36th Annual Pregnancy Meeting in Atlanta, Georgia.

Read More

Sera Prognostics Announces Clinical Study Data Selected for Presentation at the Society for Maternal-Fetal Medicine’s 36th Annual Pregnancy Meeting

January 7, 2016 — Sera Prognostics, Inc., a women’s healthcare company, today announced that findings from the 5,501 patient Proteomic Assessment of Preterm Risk (PAPR) study will be reported in an oral presentation during the Society for Maternal-Fetal Medicine’s (SMFM) 36th Annual Pregnancy Meeting™ in Atlanta, February 1-6, 2016.

Read More

Sera Prognostics Announces Early Limited Commercial Access of its PreTRM™ Test

October 19, 2015 —Sera Prognostics, Inc., a women’s healthcare company, today announced a program for early limited commercial access to PreTRM™, a proteomic biomarker blood test designed to provide an early, objective, and individualized assessment of a woman’s risk of preterm birth.

Read More